Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactol
- Development stage
- Phase 3
- Lead developer
- Bioplus Life Sciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactol is a commercial synbiotic formulation developed by Bioplus Life Sciences and marketed by Natures Only. It is designed to support gastrointestinal health and manage symptoms of various gastrointestinal disorders, including irritable bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO), functional constipation, and functional abdominal pain. Lactol is co-formulated as a tablet, capsule, or sachet containing the lactic acid-producing probiotic bacterium *Bacillus coagulans* (historically referred to as *Lactobacillus sporogenes*) and the prebiotic fructo-oligosaccharides (FOS). The combination of the spore-forming probiotic, which is highly resistant to gastric acid, and the prebiotic FOS enhances the survival, germination, and proliferation of beneficial bacteria in the large intestine. This helps restore normal gut microbiota, improve digestion, and modulate the local immune response.
- Brand names
- Lactol
- Other names
- Bacillus coagulans + fructo-oligosaccharidesLactobacillus sporogenes + fructo-oligosaccharides
Beyond the preview
Go deeper on Lactol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactol.